BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Inclusion Criteria: * Histologically documented diagnosis of squamous cell carcinoma of the head/neck including nasopharyngeal carcinomas (lymphepithelioma histology is ok if criteria 2 is met) * Patients must have progressed on prior platinum based therapy (or have become intolerant) prior to enrollment on this study * Prior anti-PD-1 or other immunotherapy is acceptable * Known FGFR genetic alterations (specifically FGFR1-3 mutation, amplification, or translocation) via deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) based assay. * The following genetic aberrations will be screened for: * FGFR1 amplification, FGFR1 somatic mutations, FGFR1 translocations * FGFR2 somatic mutations, FGFR2 translocations, FGFR2 amplification * FGFR3 somatic mutations, FGFR3 translocations, FGFR3 amplification * Other genetic FGF/FGFR pathway aberrations may be acceptable should such genetic changes be observed to emerge and require approval per the lead investigator for enrollment. * The number of enrolled patients with each type of genetic aberration may be limited at the discretion of the lead investigator. * Consent to undergo a fresh biopsy in case of benefit from therapy and subsequent progression * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Patients must provide written informed consent prior to any screening procedures * Aged 18 years or older * Willing and able to comply with scheduled visits, treatment plan and laboratory tests…